RON receptor tyrosine kinase as a target for delivery of chemodrugs by antibody directed pathway for cancer cell cytotoxicity

Molecular Pharmaceutics

Volumn 7, Issue 2, 2010, Pages 386-397

  Guin, Sunny ^a   Yao, Hang Ping ^b   Wang, Ming Hai ^a,b,c  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b ZHEJIANG UNIVERSITY   (China)

^c TEXAS TECH UNIVERSITY   (United States)

Author keywords

Drug delivery; Immunoliposomes; Monoclonal antibody; Receptor tyrosine kinase; Targeted therapy

Indexed keywords

CYTOKINE; DOXORUBICIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOLIPOSOME; MACROGOL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ZT C1; MONOCLONAL ANTIBODY ZT G4; PROTEIN TYROSINE KINASE; RON RECEPTOR TYROSINE KINASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG UPTAKE; ENDOCYTOSIS; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IC 50; INTERNALIZATION; PRIORITY JOURNAL; TIME;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; COLONIC NEOPLASMS; DOXORUBICIN; FLOW CYTOMETRY; HUMANS; IMMUNOPRECIPITATION; LIPOSOMES; MICE; MODELS, THEORETICAL; NIH 3T3 CELLS; PHOSPHORYLATION; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 77950576925     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp900168v     Document Type: Article

References (34)

1. Ricart, A. D.; Tolcher, A. W. Technology insight: cytotoxic drug immunoconjugates for cancer therapy Nat. Clin. Pract. Oncol. 2007, 4, 245-255
2. Stasi, R.; Evangelista, M. L.; Buccisano, F.; Venditti, A.; Amadori, S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia Cancer Treat. Rev. 2008, 34, 49-60
3. Cho, K.; Wang, X.; Nie, S.; Chen, Z. G.; Shin, D. M. Therapeutic nanoparticles for drug delivery in cancer Clin. Cancer Res. 2008, 14, 1310-1316
4. Carter, P. Improving the efficacy of antibody-based cancer therapies Nat. Rev. Cancer 2001, 1, 118-129
5. Mamot, C.; Drummond, D. C.; Noble, C. O.; Kallab, V.; Guo, Z.; Hong, K.; Kirpotin, D. B.; Park, J. W. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo Cancer Res. 2005, 65, 11631-11638
6. Patra, C. R.; Bhattacharya, R.; Wang, E.; Katarya, A.; Lau, J. S.; Dutta, S.; Michael Muders, M.; Wang, S.; Buhrow, S. A.; Safgren, S. L.; Yaszemski, M. J.; Reid, M. J.; Ames, M. M.; Mukherjee, P.; Mukhopadhyay, D. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent Cancer Res. 2008, 68, 1970-1978
7. Mamot, C.; Drummond, D. C.; Greiser, U.; Hong, K.; Kirpotin, D. B.; Marks, J. D.; Park, J. W. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells Cancer Res. 2003, 63, 3154-3161
8. Ronsin, C.; Muscatelli, F.; Mattei, M. G.; Breathnach, R. A novel putative receptor protein tyrosine kinase of the met family Oncogene 1993, 8, 1195-1202
9. Wang, M. H.; Lee, W.; Luo, Y. L.; Weis, M. T.; Yao, H. P. Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells J. Pathol. 2007, 213, 402-411
10. Wang, M. H.; Ronsin, C.; Gesnel, M. C.; Coupey, L.; Skeel, A.; Leonard, E. J.; Breathnach, R. Identification of the ron gene product as the receptor for the human macrophage stimulating protein Science 1994, 266, 117-119
11. Waltz, S. E.; McDowell, S. A.; Muraoka, R. S.; Air, E. L.; Flick, L. M.; Chen, Y. Q.; Wang, M. H.; Degen, S. J. F. Functional characterization of domains contained in hepatocyte growth factor-like protein J. Biol. Chem. 1997, 272, 30526-30537
12. Wang, M. H.; Yao, H. P.; Zhou, Y. Q. Oncogenesis of RON receptor tyrosine kinase: a molecular target for malignant epithelial cancers Acta Pharmacol. Sin. 2006, 27, 641-650
13. Wagh, P. K.; Peace, B. E.; Waltz, S. E. Met-related receptor tyrosine kinase Ron in tumor growth and metastasis Adv. Cancer Res. 2008, 100, 1-33
14. Penengo, L.; Rubin, C.; Yarden, Y.; Gaudino, G. c-Cbl is a critical modulator of the Ron tyrosine kinase receptor Oncogene 2003, 22, 3669-3679
15. O'Toole, J. M.; Rabenau, K. E.; Burns, K.; Lu, D.; Mangalampalli, V.; Balderes, P.; Covino, N.; Bassi, R.; Prewett, M.; Gottfredsen, K. J.; Thobe, M. N.; Cheng, Y.; Li, Y.; Hicklin, D. J.; Zhu, Z.; Waltz, S. E.; Hayman, M. J.; Ludwig, D. L.; Pereira, D. S. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member Cancer Res. 2006, 66, 9162-9170
16. Zhang, Y.; Kaplan-Lefko, P. J.; Rex, K.; Yang, Y.; Moriguchi, J.; Osgood, T.; Mattson, B.; Coxon, A.; Reese, M.; Kim, T. S.; Lin, J.; Chen, A.; Burgess, T. L.; Dussault, I. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo Cancer Res. 2008, 68, 6680-6687
17. Dussault, I.; Bellon, S. F. From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer Anticancer Agents Med. Chem. 2009, 9, 221-229
18. Yao, H. P.; Luo, Y. L.; Feng, L.; Cheng, L. F.; Lu, Y.; Li, W.; Wang, M. H. Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase Cancer Biol. Ther. 2006, 5, 1179-1186
19. Ishida, T.; Iden, D. L.; Allen, T. M. A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs FEBS Lett. 1999, 460, 129-133
20. Iden, D. L.; Allen, T. M. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach Biochim. Biophys. Acta 2001, 1513, 207-216
21. Lu, Y.; Yao, H. P.; Wang, M. H. Significance of the entire C-terminus in biological activities mediated by the RON receptor tyrosine kinase and its oncogenic variant RON160 J. Exp. Clin. Cancer Res. 2008, 27, 55-61
22. Sapra, P.; Allen, T. M. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs Cancer Res. 2002, 62, 7190-7194
23. Miller, C. R.; Bondurant, B.; McLean, S. D.; McGovern, K. A.; O'Brien, D. F. Liposome-Cell Interactions in Vitro: Effect of Liposome Surface Charge on the Binding and Endocytosis of Conventional and Sterically Stabilized Liposomes Biochemistry 1998, 37, 12875-12883
24. Wang, M. H.; Dlugosz, A. A.; Sun, Y.; Suda, T.; Skeel, A.; Leonard, E. J. Macrophage-stimulating protein induces proliferation and migration of murine keratinocytes Exp. Cell Res. 1996, 226, 39-46
25. Mamot, C.; Ritschard, R.; Kung, W.; Park, J. W.; Herrmann, R.; Rochlitz, C. F. EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells J. Drug Targeting 2006, 14, 215-223
26. Sofou, S.; Sgouros, G. Antibody-targeted liposomes in cancer therapy and imaging Expert Opin. Drug Delivery 2008, 5, 189-204
27. Dong, X.; Mattingly, C. A.; Tseng, M. T.; Cho, J. M.; Liu, Y.; Adams, V. R.; Mumper, R. J. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP Cancer Res. 2009, 69, 3918-3926
28. Kesarwala, A. H.; Samrakandi, M. M.; Piwnica-Worms, D. Proteasome inhibition blocks ligand-induced dynamic processing and internalization of epidermal growth factor receptor via altered receptor ubiquitination and phosphorylation Cancer Res. 2009, 69, 976-983
29. Cheson, B. D.; Leonard, J. P. Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma N. Engl. J. Med. 2005, 359, 613-626
30. Yoshida, T.; Okamoto, I.; Okabe, T.; Iwasa, T.; Satoh, T.; Nishio, K.; Fukuoka, M.; Nakagawa, K. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk Int. J. Cancer 2008, 122, 1530-1538
31. Ciardiello, F.; Tortora, G. EGFR Antagonists in Cancer Treatment N. Engl. J. Med. 2008, 358, 1160-1174
32. Van Cutsem, E.; Kohne, C. H.; Hitre, E.; Zaluski, J.; Chang Chien, C. R.; Makhson, A.; D'Haens, G.; Pint́ er, T.; Lim, R.; Bodoky, G.; Roh, J. K.; Folprecht, G.; Ruff, P.; Stroh, C.; Tejpar, S.; Schlichting, M.; Nippgen, J.; Rougier, P. Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer N. Engl. J. Med. 2009, 360, 1408-1417
33. Mamot, C.; Ritschard, R.; Küng, W.; Park, J. W.; Herrmann, R.; Rochlitz, C. F. EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells J. Drug Targeting 2006, 14, 215-223
34. Drummond, D. C.; Meyer, O.; Hong, K.; Kirpotin, D. B.; Papahadjopoulos, D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors Pharmacol. Rev. 1999, 51, 691-743